The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple ...

The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug ...

PTC Therapeutics could boost revenue with vatiquinone for Friedreich's ataxia. Find out why PTCT stock is poised for growth ...

While the IRA architects were building their anti-innovation government drug pricing plan, they also included a provision to ...

Small-Cap Firms Dominate Market Rally. In this article, we are going to take a look at where Plus Therapeutics, Inc.

Shares of Plus Therapeutics, Inc. PSTV were up a whopping 311.4% on March 6 after the company announced that the FDA has ...

The FDA granted orphan drug status to rhenium-186 obisbemeda for treating leptomeningeal metastases in lung cancer.

ENCell’s investigational drug EN001 has been granted Orphan Drug Designation by the FDA for the treatment of ...

Adds to Extensive Preclinical and Early Clinical Evidence that Nebokitug Interferes with Key Features of Systemic Sclerosis. TEL AVIV, Israel, (GLOBE NEWSWIRE) -- C ...

Plus Therapeutics (PSTV) soars with FDA's Orphan Drug Designation for Rhenium Obisbemeda, targeting rare leptomeningeal metastases.

Plus Therapeutics (PSTV) announces that the U.S. Food and Drug Administration has granted Orphan Drug Designation to Rhenium Obisbemeda for the ...

Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company” or “Plus Therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for ...